GlassScriptPhysician profile
Tovia M Smith
NPI 1417160524
$1,153.31
in general payments reported to CMS, 2019-2025
14 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2021: $189 · 2022: $53.79 · 2023: $176 · 2024: $146 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $248.00 | 2021-2023 | Axonics |
| Boston Scientific Corporation | $174.37 | 2019-2024 | Upsylon, Solyx Sis System |
| Abbvie INC. | $165.07 | 2023-2025 | Liletta |
| Femselect INC. | $131.82 | 2025 | Enplace |
| Medtronic USA, INC. | $118.58 | 2019 | |
| Allergan, INC. | $88.47 | 2019 | |
| Therapeuticsmd, INC. | $44.72 | 2019 | |
| Astellas Pharma US INC | $39.32 | 2019-2023 | Veozah |
| Hologic Sales and Service, LLC | $38.98 | 2024 | Acessa Provu System, Aptima |
| Mayne Pharma Commercial LLC | $31.57 | 2021-2022 | |
| Myovant Sciences INC. | $23.10 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $20.01 | 2019 | |
| Urovant Sciences INC | $16.50 | 2022 | |
| Rochester Medical Corporation | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tovia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.